羟氯喹对老年睡眠呼吸暂停患者内皮功能影响的研究方案
本研究为随机临床试验方案,拟从现有队列中招募65岁以上中重度睡眠呼吸暂停患者,每日给予羟氯喹400 mg持续8周,以血流介导的血管舒张和外周动脉张力测定评估内皮功能,初步探索羟氯喹改善内皮功能及降低心血管风险标志物的疗效。
要点
- 对象为65岁以上中重度睡眠呼吸暂停患者,干预为羟氯喹400 mg/日共8周。
- 主要评估内皮功能:血流介导的血管舒张(金标准)和外周动脉张力测定。
- 若初步显示改善,计划设计多中心随机临床试验以验证结果。
核心结论
- 研究旨在初步获取羟氯喹改善老年睡眠呼吸暂停患者内皮功能及降低心血管风险标志物的疗效证据。
- 若初步改善成立,拟进一步设计多中心随机临床试验确认。
研究设计与样本
- 随机临床试验,从正在进行的队列中招募65岁以上中重度睡眠呼吸暂停患者。
- 干预为羟氯喹400 mg/日,持续8周。
- 内皮功能采用血流介导的肱动脉舒张(金标准)和外周动脉张力测定评估。
关键数值与推荐
- 纳入标准:年龄大于65岁且为中重度睡眠呼吸暂停。
- 羟氯喹剂量:400 mg/日,疗程8周。
- 主要评估方法:血流介导的血管舒张和外周动脉张力测定。
临床怎么用
- 本研究为方案阶段,尚无临床实践推荐;结果将用于评估羟氯喹在非自身免疫病人群中的心血管保护潜力。
局限性
- 样本来源于现有队列,采用便利抽样。
- 研究定位为初步证据,需后续多中心试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleep apnea and coronary artery disease are prevalent and relevant diseases. The mechanism by which sleep apnea leads to coronary artery disease remains unclear. Intermittent hypoxia, caused by sleep apnea, leads to inflammation and consequent endothelial dysfunction. Endothelial dysfunction precedes the development of atherosclerotic disease and the occurrence of cardiovascular events. Agents that potentially act to improve endothelial function can help prevent cardiovascular events. Patients using immunomodulators due to rheumatic diseases have a lower prevalence of cardiovascular diseases. However, the potential cardioprotective effect of these drugs in patients without autoimmune diseases is not clear. Hydroxychloroquine (HCQ) is an immunomodulator used to treat rheumatoid arthritis and systemic lupus erythematosus. In addition to its anti-inflammatory properties, HCQ reduces cholesterol and blood glucose levels and has antithrombotic effects. The drug is inexpensive and widely available. Adverse effects of HCQ are rare and occur more frequently with high doses. OBJECTIVE: In this randomized clinical trial, the effect of HCQ treatment on endothelial function will be tested in seniors with sleep apnea. METHODS: We will recruit participants over the age of 65 and with moderate-severe sleep apnea from an ongoing cohort. We chose to use this sample already evaluated for sleep apnea for reasons of convenience, but also because the elderly with sleep apnea are vulnerable to heart disease. Endothelial function will be assessed by examining flow-mediated dilation of the brachial artery, the gold standard method, considered an independent predictor of cardiovascular events in the general population and by peripheral arterial tonometry, the most recent and most easily obtained method. Hydroxychloroquine will be used at a dose of 400 mg/daily for 8 weeks. DISCUSSION: Our study aims to obtain evidence, albeit preliminary, of the efficacy of hydroxychloroquine in improving endothelial function and reducing cardiovascular risk markers. If the improvement occurs, we plan to design a randomized multicenter clinical trial to confirm the findings. TRIAL REGISTRATION: ClinicalTrials.gov NCT04161339 . Registered on November 2019.
引用
- Tedesco Silva LM, Cortes A, Rossi B, et al. Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study protocol for a randomized clinical trial. Trials. 2021. PMID: 34535165. doi:10.1186/s13063-021-05610-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。